高级检索
赵鸿萍, 蒋宏民, 相秉仁. 近5年全球在研心血管药物研发热点靶标及趋势分析[J]. 中国药科大学学报, 2012, 43(6): 573-576.
引用本文: 赵鸿萍, 蒋宏民, 相秉仁. 近5年全球在研心血管药物研发热点靶标及趋势分析[J]. 中国药科大学学报, 2012, 43(6): 573-576.
ZHAO Hong-ping, JIANG Hong-min, XIANG Bing-ren. Analysis on the hot spot targets and tendency of the global cardiovascular drug development in recent 5 years[J]. Journal of China Pharmaceutical University, 2012, 43(6): 573-576.
Citation: ZHAO Hong-ping, JIANG Hong-min, XIANG Bing-ren. Analysis on the hot spot targets and tendency of the global cardiovascular drug development in recent 5 years[J]. Journal of China Pharmaceutical University, 2012, 43(6): 573-576.

近5年全球在研心血管药物研发热点靶标及趋势分析

Analysis on the hot spot targets and tendency of the global cardiovascular drug development in recent 5 years

  • 摘要: 对Thomsonpharma检索获得的2008年1月至2012年3月全球在研的3 723个心血管药物进行统计分析,获得了近5年心血管药物研发的热点靶标、上市药物数量最多及上市药物比例最高的靶标、研发中止药物数量最多及研发中止药物比例最高的靶标,对部分心血管药物研发的趋势进行了预测。

     

    Abstract: This paper applies statistic analysis to the 3 723 cardiovascular drugs derived from the search of Thomsonpharma, which were developed during the period of January 1,2008 to March 20,2012.The targets of the cardiovascular drugs for the past 5 years are obtaind as follows:the hot spots targets,the launched targets which are higest both in number and percentage and the discontined targets which are higest both in number and percentage.Furthermore, some developmental tendencies are revealed.

     

/

返回文章
返回